Cargando…
Combining VEGF receptor inhibitors and angiotensin-(1–7) to target renal cell carcinoma
Resistance to tyrosine kinase inhibitors of the vascular endothelial growth factor receptor inevitably develops in most patients with metastatic kidney cancer. Our recent findings demonstrate that addition of angiotensin-(1-7) peptide can be a potential therapy that delays such resistance.
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8489949/ https://www.ncbi.nlm.nih.gov/pubmed/34616864 http://dx.doi.org/10.1080/23723556.2021.1918529 |